🇺🇸 FDA
Patent

US 7422738

Combined cancer treatment methods using antibodies to aminophospholipids

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 7422738 (Combined cancer treatment methods using antibodies to aminophospholipids) held by The Board of Regents of the University of Texas System expires Mon Sep 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 09 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
53
CPC classes
A61K, A61K2039/505, A61K38/00, A61K47/6849, A61K49/04